{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:43:07Z","timestamp":1792590187611,"version":"4.5.0"},"reference-count":18,"publisher":"MyJove Corporation","issue":"230","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/68974","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:01:10Z","timestamp":1775257270000},"source":"Crossref","is-referenced-by-count":1,"title":["Gestational Trophoblastic Neoplasia in Perimenopausal Women: Clinical Analysis, Case Series, and Literature Review"],"prefix":"10.3791","author":[{"given":"Ling","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12094-017-1793-0","type":"journal-article","article-title":"SEOM clinical guidelines in gestational trophoblastic disease (2017)","volume":"20","author":"Santaballa","year":"2017","unstructured":"Santaballa, A. et al. SEOM clinical guidelines in gestational trophoblastic disease (2017). Clin Transl Oncol. 20 (1), 38-46 (2018).","journal-title":"Clin Transl Oncol"},{"issue":"Suppl 2","key":"ref2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.12615","type":"journal-article","article-title":"Update on the diagnosis and management of gestational trophoblastic disease","volume":"143","author":"Ngan","year":"2018","unstructured":"Ngan, H. Y. S. et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 143 (Suppl 2), 79-85 (2018).","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/01443615.2013.771159","type":"journal-article","article-title":"The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome","volume":"33","author":"Savage","year":"2013","unstructured":"Savage, P. M. et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 33 (4), 406-411 (2013).","journal-title":"J Obstet Gynaecol"},{"issue":"4","key":"ref4","first-page":"469","type":"journal-article","article-title":"Gestational trophoblastic disease and \u201csecond child\u201d pregnancy","volume":"38","author":"An","year":"2017","unstructured":"An, R. F., Fang, J. Gestational trophoblastic disease and \u201csecond child\u201d pregnancy. J Xian Jiaotong Univ Med Ed. 38 (4), 469-473 (2017).","journal-title":"J Xian Jiaotong Univ Med Ed"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/0002-9378(84)90554-4","type":"journal-article","article-title":"Sex assignment in gestational trophoblastic neoplasia","volume":"148","author":"Davis","year":"1984","unstructured":"Davis, J. R. et al. Sex assignment in gestational trophoblastic neoplasia. Am J Obstet Gynecol. 148 (6), 722-725 (1984).","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(07)70204-8","type":"journal-article","article-title":"Gestational trophoblastic neoplasia\u2014pathogenesis and potential therapeutic targets","volume":"8","author":"Shih","year":"2007","unstructured":"Shih, I. M. Gestational trophoblastic neoplasia\u2014pathogenesis and potential therapeutic targets. Lancet Oncol. 8 (7), 642-650 (2007).","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"ref7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijgo.13877","type":"journal-article","article-title":"Diagnosis and management of gestational trophoblastic disease: 2021 update","volume":"155","author":"Ngan","year":"2021","unstructured":"Ngan, H. Y. S. et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynecol Obstet. 155 (Suppl 1), 86-93 (2021).","journal-title":"Int J Gynecol Obstet"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5001\/omj.2019.39","type":"journal-article","article-title":"Gestational trophoblastic disease at Sultan Qaboos University Hospital: prevalence, risk factors, histological features, sonographic findings, and outcomes","volume":"34","author":"Al Riyami","year":"2019","unstructured":"Al Riyami, N. et al. Gestational trophoblastic disease at Sultan Qaboos University Hospital: prevalence, risk factors, histological features, sonographic findings, and outcomes. Oman Med J. 34 (3), 200-204 (2019).","journal-title":"Oman Med J"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.31557\/APJCP.2020.21.11.3325","type":"journal-article","article-title":"Efficacy of oral vitamin A in reducing \u03b2-hCG levels in low-risk gestational trophoblastic neoplasia patients","volume":"21","author":"Hidayat","year":"2020","unstructured":"Hidayat, Y. M. et al. Efficacy of oral vitamin A in reducing \u03b2-hCG levels in low-risk gestational trophoblastic neoplasia patients. Asian Pac J Cancer Prev. 21 (11), 3325-3329 (2020).","journal-title":"Asian Pac J Cancer Prev"},{"issue":"12","key":"ref10","first-page":"CD008891","type":"journal-article","article-title":"Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia","volume":"2016","author":"Alazzam","year":"2016","unstructured":"Alazzam, M. et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016 (12), CD008891 (2016).","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.ajog.2021.05.006","type":"journal-article","article-title":"Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France","volume":"225","author":"Descargues","year":"2021","unstructured":"Descargues, P. et al. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France. Am J Obstet Gynecol. 225 (4), 401.e1-401.e8 (2021).","journal-title":"Am J Obstet Gynecol"},{"issue":"25","key":"ref12","first-page":"00176","type":"journal-article","article-title":"Presence of atypical extravillous trophoblast foci is an independent predictor of the risk of progression to postmolar neoplasia","volume":"S0002-9378","author":"Schoenen","year":"2025","unstructured":"Schoenen, S. et al. Presence of atypical extravillous trophoblast foci is an independent predictor of the risk of progression to postmolar neoplasia. Am J Obstet Gynecol. S0002-9378 (25), 00176-0 (2025).","journal-title":"Am J Obstet Gynecol"},{"issue":"25","key":"ref13","first-page":"00811","type":"journal-article","article-title":"Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial","volume":"S0923-7534","author":"Jiang","year":"2025","unstructured":"Jiang, F. et al. Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial. Ann Oncol. S0923-7534 (25), 00811-7 (2025).","journal-title":"Ann Oncol"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"381.e1","DOI":"10.1016\/j.ajog.2024.09.115","type":"journal-article","article-title":"Fc\u03b3R3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia","volume":"232","author":"Msika","year":"2024","unstructured":"Msika, A. et al. Fc\u03b3R3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia. Am J Obstet Gynecol. 232 (4), 381.e1-381.e11 (2024).","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/AOG.0000000000004240","type":"journal-article","article-title":"Gestational trophoblastic disease: current evaluation and management","volume":"137","author":"Soper","year":"2021","unstructured":"Soper, J. T. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. 137 (2), 355-370 (2021).","journal-title":"Obstet Gynecol"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(21)00262-X","type":"journal-article","article-title":"Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre retrospective cohort study","volume":"22","author":"Braga","year":"2021","unstructured":"Braga, A. et al. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre retrospective cohort study. Lancet Oncol. 22 (8), 1188-1198 (2021).","journal-title":"Lancet Oncol"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/AOG.0000000000005214","type":"journal-article","article-title":"Perioperative considerations for hysterectomy in second-trimester molar pregnancy","volume":"142","author":"Applebaum","year":"2023","unstructured":"Applebaum, J., Mulugeta-Gordon, L., Mokkarala, S., Salva, C. R. Perioperative considerations for hysterectomy in second-trimester molar pregnancy. Obstet Gynecol. 142 (1), 211-214 (2023).","journal-title":"Obstet Gynecol"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S1470-2045(21)00460-5","type":"journal-article","article-title":"Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm open-label phase 2 trial","volume":"22","author":"Cheng","year":"2021","unstructured":"Cheng, H. et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm open-label phase 2 trial. Lancet Oncol. 22 (11), 1609-1617 (2021).","journal-title":"Lancet Oncol"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/68974\/gestational-trophoblastic-neoplasia-perimenopausal-women-clinical","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:06:08Z","timestamp":1792587968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/68974\/gestational-trophoblastic-neoplasia-perimenopausal-women-clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":18,"journal-issue":{"issue":"230","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/68974","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}